Donate

Industry News

On June 7th, 2018, Genentech announced a new web portal for patients and caregivers intended to provide timely and accurate information on targeted serious adverse events of interest for HEMLIBRA.  Earlier this year, Genentech launched a similar site specifically for health care providers.

In announcing the launch, Genentech stated “This website is meant to serve as just one of the ways we will provide updated, verified safety information to the hemophilia community, specifically about thrombotic microangiopathy, serious thrombotic events (blood clots), and fatalities in patients taking emicizumab-kxwh, whether or not such events are related to emicizumab-kxwh.”

HFA and NHF do not recommend, endorse or make any representation about the efficacy, appropriateness or suitability of any specific products, treatments, or opinions. Please consult your physician before use of any treatments.

Facebook Comments


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.